Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00383864
Recruitment Status : Completed
First Posted : October 4, 2006
Last Update Posted : October 6, 2006
Information provided by:
Hospital Clinic of Barcelona

Brief Summary:
The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation. The only approved drugs for treatment of hepatitis C are pegylated interferon and ribavirin.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: Pegylated interferon and ribavirin Phase 4

Detailed Description:
Hepatitis C recurrence after liver transplantation remains the main cause of graft loss after liver transplantation. Several strategies can be used to prevent or treat hepatitis C in the setting of liver transplantation. There are no controlled studies evaluating the efficacy and safety of antiviral treatment (using pegylated interferon and ribavirin) in liver transplant recipients. The main endpoint of this study was: 1) histological outcomes (effect of antiviral treatment on disease progression, i.e. liver fibrosis). The secondary endpoint were 1) Sustained virological response (persistent HCV-RNA clearance) and 2) Safety of pegylated interferon and ribavirin

Study Type : Interventional  (Clinical Trial)
Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation
Study Start Date : July 2001
Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Histological improvement (decrease in at least one fibrosis stage in follow-up liver biop

Secondary Outcome Measures :
  1. Sustained virological response (persistent HCV-RNA negativation)
  2. Safety of antiviral therapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic hepatitis C defined by liver biopsy and presence of HCV-RNA
  • More than 6 months from liver transplantation
  • Written inform consent

Exclusion Criteria:

  • Severe hepatitis C recurrence (F3-F4 fibrosis stage, cholestatic hepatitis)
  • Double liver-kidney transplantation
  • Leucopenia (2000) or thrombocytopenia (40.000)
  • Anemia (Hemoglobin lower than 10 g/dL)
  • Renal failure (creatinine > 2 mg/dL)
  • Autoimmune disease
  • All contraindications for interferon and ribavirin therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00383864

Liver Unit, Hospital Clinic
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Principal Investigator: Xavier Forns, MD Liver Unit, Hospital Clinic, Barcelona

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00383864     History of Changes
Other Study ID Numbers: PEG/RBV POST-TOH
First Posted: October 4, 2006    Key Record Dates
Last Update Posted: October 6, 2006
Last Verified: October 2006

Keywords provided by Hospital Clinic of Barcelona:
liver fibrosis
portal pressure
antiviral therapy

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action